Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours

[1]  T. Graeber,et al.  Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. , 2017, Cancer discovery.

[2]  J. Wargo,et al.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy , 2016, Cell.

[3]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[4]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[5]  S. H. van der Burg,et al.  TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors. , 2016, The Journal of clinical investigation.

[6]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[7]  J. Gartner,et al.  Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. , 2015, The Journal of clinical investigation.

[8]  S. Ferrone,et al.  Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen Class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy* , 2015, The Journal of Biological Chemistry.

[9]  M. Hidalgo,et al.  Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice. , 2015, Cancer research.

[10]  S. Grupp,et al.  Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street , 2015, The Journal of Immunology.

[11]  Julie G. Burel,et al.  Exome Sequencing to Predict Neoantigens in Melanoma , 2015, Cancer Immunology Research.

[12]  E. Mardis,et al.  A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells , 2015, Science.

[13]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[14]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[15]  P. Validire,et al.  CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients , 2015, The Journal of Immunology.

[16]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[17]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[18]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[19]  S. Rosenberg,et al.  Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions , 2014, Clinical Cancer Research.

[20]  P. Coulie,et al.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy , 2014, Nature Reviews Cancer.

[21]  S. Rosenberg,et al.  Exploiting the curative potential of adoptive T‐cell therapy for cancer , 2014, Immunological reviews.

[22]  P. Romero,et al.  Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. , 2013, Cancer research.

[23]  S. H. van der Burg,et al.  New Role of Signal Peptide Peptidase To Liberate C-Terminal Peptides for MHC Class I Presentation , 2013, The Journal of Immunology.

[24]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[25]  Zhao Yang,et al.  Identification of new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from neuritin , 2013, Journal of Neuro-Oncology.

[26]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[27]  F. Mami-Chouaib,et al.  TAP expression level in tumor cells defines the nature and processing of MHC class I peptides for recognition by tumor‐specific cytotoxic T lymphocytes , 2013, Annals of the New York Academy of Sciences.

[28]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[29]  P. Validire,et al.  Different Expression Levels of the TAP Peptide Transporter Lead to Recognition of Different Antigenic Peptides by Tumor-Specific CTL , 2011, The Journal of Immunology.

[30]  S. High,et al.  Eeyarestatin 1 Interferes with Both Retrograde and Anterograde Intracellular Trafficking Pathways , 2011, PloS one.

[31]  R. Ferris,et al.  Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes , 2011, Cancer Immunology, Immunotherapy.

[32]  S. H. van der Burg,et al.  CD8+ T Cell Responses against TAP-Inhibited Cells Are Readily Detected in the Human Population , 2010, The Journal of Immunology.

[33]  Qiuyan Wang,et al.  The ERAD Inhibitor Eeyarestatin I Is a Bifunctional Compound with a Membrane-Binding Domain and a p97/VCP Inhibitory Group , 2010, PloS one.

[34]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[35]  C. Aspord,et al.  A Novel Cancer Vaccine Strategy Based on HLA-A*0201 Matched Allogeneic Plasmacytoid Dendritic Cells , 2010, PloS one.

[36]  S. H. van der Burg,et al.  The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects , 2010, The Journal of experimental medicine.

[37]  S. H. van der Burg,et al.  The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects , 2010, The Journal of Experimental Medicine.

[38]  P. Validire,et al.  Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. , 2009, Cancer research.

[39]  M. Einstein,et al.  Genetic Variants in TAP Are Associated with High-Grade Cervical Neoplasia , 2009, Clinical Cancer Research.

[40]  Jeffrey L. Brodsky,et al.  One step at a time: endoplasmic reticulum-associated degradation , 2008, Nature Reviews Molecular Cell Biology.

[41]  V. Lazar,et al.  Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway , 2008, Proceedings of the National Academy of Sciences.

[42]  Qiuyan Wang,et al.  Inhibition of p97-dependent Protein Degradation by Eeyarestatin I* , 2008, Journal of Biological Chemistry.

[43]  Wilfred A. Jefferies,et al.  Epigenetic Control of the Immune Escape Mechanisms in Malignant Carcinomas , 2007, Molecular and Cellular Biology.

[44]  V. Lazar,et al.  αEβ7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis , 2007, The Journal of experimental medicine.

[45]  A. Cooper,et al.  Misfolded proteins traffic from the endoplasmic reticulum (ER) due to ER export signals. , 2006, Molecular biology of the cell.

[46]  R. Offringa,et al.  Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants , 2006, Nature Medicine.

[47]  R. Tampé,et al.  Modulation of the antigen transport machinery TAP by friends and enemies , 2006, FEBS letters.

[48]  M. Kloor,et al.  Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. , 2005, Cancer research.

[49]  S. Ferrone,et al.  A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. , 2005, Journal of immunological methods.

[50]  B. Seliger,et al.  Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome , 2005, Clinical Cancer Research.

[51]  Franca Ronchese,et al.  The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. , 2004, Journal of immunological methods.

[52]  A. McMichael,et al.  Requirement of the Proteasome for the Trimming of Signal Peptide-derived Epitopes Presented by the Nonclassical Major Histocompatibility Complex Class I Molecule HLA-E* , 2003, Journal of Biological Chemistry.

[53]  D. Speiser,et al.  Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[54]  N. Hayashi,et al.  Impaired expression of proteasome subunits and human leukocyte antigens class I in human colon cancer cells , 2003, Journal of gastroenterology and hepatology.

[55]  D. Speiser,et al.  Antigenicity and immunogenicity of Melan‐A/MART‐1 derived peptides as targets for tumor reactive CTL in human melanoma , 2002, Immunological reviews.

[56]  F. Mami-Chouaib,et al.  Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[57]  R. Tampé,et al.  Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. , 2001, Cancer research.

[58]  S. Filetti,et al.  Na(+)/I(-) symporter and Pendred syndrome gene and protein expressions in human extra-thyroidal tissues. , 2001, European journal of endocrinology.

[59]  C. Huber,et al.  Transporter (TAP)‐ and proteasome‐independent presentation of a melanoma‐associated tyrosinase epitope , 2000, International journal of cancer.

[60]  F. Mami-Chouaib,et al.  Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung. , 2000, International immunology.

[61]  S. Rosenberg,et al.  Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. , 1999, Journal of immunotherapy.

[62]  B. Martoglio,et al.  Signal sequences: more than just greasy peptides. , 1998, Trends in cell biology.

[63]  J. Coligan,et al.  Recognition of Human Histocompatibility Leukocyte Antigen (HLA)-E Complexed with HLA Class I Signal Sequence–derived Peptides by CD94/NKG2 Confers Protection from Natural Killer Cell–mediated Lysis , 1998, The Journal of experimental medicine.

[64]  J. Bell,et al.  HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C , 1998, Nature.

[65]  P. Romero,et al.  Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. , 1998, Journal of immunology.

[66]  B. Martoglio,et al.  Signal peptide fragments of preprolactin and HIV‐1 p‐gp160 interact with calmodulin , 1997, The EMBO journal.

[67]  R. Tampé,et al.  A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer , 1996, Nature Genetics.

[68]  S. H. van der Burg,et al.  Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. , 1996, Journal of immunology.

[69]  J. Karbach,et al.  Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[70]  A. Pugsley.  The complete general secretory pathway in gram-negative bacteria. , 1993, Microbiological reviews.

[71]  R. Henderson,et al.  HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. , 1992, Science.

[72]  R. Beynon,et al.  3,4‐Dichloroisocoumarin, a serine protease inhibitor, inactivates glycogen phosphorylase b , 1990, FEBS letters.

[73]  G. Milhaud,et al.  The complete sequence of human preprocalcitonin , 1984, FEBS letters.

[74]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.